The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
The company is completing a study of its digital microscopy system which uses a computational approach that it said enables high-speed, high-resolution scanning.
A number of labs and informatics firms are using test data to help guide the response to the virus in a spirit similar to that of initiatives like Lab 2.0.
The agreement reflects Oncocyte's strategy to establish distribution partners with existing oncology channels to extend the reach of its tests globally.
Under the agreement, Bioneer will supply instruments, nucleic acid extraction reagents, and COVID-19 test kits, which will be placed at medical institutions in Qatar.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
The firm looks to win new customers among US providers while also partnering with IVD companies to embed its lab data analysis tools in their instruments.
